Vertex Pharma (VRTX) Tops Q1 EPS by 72c, Revenues Beat; Raises FY20 Revenues Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Vertex Pharma (VRTX) Granted European CHMP Positive Opinion for KALYDECO for Children/Adolescents with CF and R117H Mutation in CFTR Gene
May 1, 2020 5:50 AM EDTVertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that the European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the label extension of KALYDECO® (ivacaftor), to include the treatment of children and adolescents with cystic fibrosis (CF), ages 6 months and older weighing at least 5 kg who have the R117H mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Todays announcement is important for young people with CF, as early intervention and treatment of this devastating and progressive disease is key to... More
RBC Capital Downgrades Vertex (VRTX) to Sector Perform
April 28, 2020 5:12 AM EDTRBC Capital analyst Brian Abrahams downgraded Vertex (NASDAQ: VRTX) from Outperform to Sector Perform with a price target of $260.00 (from $250.00).
The analyst comments "We remain bullish on the company's fundamentals, with high growth prospects for its core cystic fibrosis franchise, strong adoption of launching drug Trikafta, good insulation from COVID-19 likely... More
Vertex Pharma (VRTX), Affinia Therapeutics Establish Multi-Year Collaboration to Discover and Develop Novel AAV Capsids for Genetic Therapies
April 27, 2020 8:32 AM EDTVertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Affinia Therapeutics announced today that the two companies have entered into a strategic research collaboration to engineer novel adeno-associated virus (AAV) capsids to deliver transformative genetic therapies to people with serious diseases. Affinia Therapeutics proprietary AAVSmartLibrary and associated technology provides capsids for improved tissue tropism, manufacturability and pre-existing immunity. The collaboration will leverage Affinia Therapeutics capsid engineering expertise and Vertexs scientific, clinical and regulatory capabilities to accelerate the development of genetic therapies for people affected by Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and cystic fibrosis (CF).
... More
